Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
NEW YORK/AMSTERDAM - Mental health-focused biopharmaceutical company atai Life Sciences (NASDAQ:ATAI), whose stock has surged over 390% in the past year according to InvestingPro data, announced Thursday the commencement of a proposed registered underwritten public offering of its common shares.
The clinical-stage company plans to grant underwriters a 30-day option to purchase additional common shares at the public offering price, less underwriting discount. Jefferies LLC will serve as lead bookrunner, with Berenberg Capital Markets LLC acting as passive bookrunner. Canaccord Genuity LLC and Oppenheimer & Co. are participating as co-managers.
atai intends to use proceeds from the offering to advance clinical development of its product candidates and for working capital and general corporate purposes. The company’s pipeline includes several psychedelic-based therapies currently in Phase 2 clinical development, including BPL-003 for treatment-resistant depression, VLS-01, and EMP-01 for social anxiety disorder. InvestingPro analysis indicates the company is currently trading above its Fair Value, though analysts have set price targets ranging from $7 to $16 per share.
The offering is subject to market conditions, with no assurance regarding completion timing or final terms. All common shares in the offering will be sold by atai.
The securities are being offered pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission on September 29, 2025. A preliminary prospectus supplement related to the offering will be filed with the SEC.
According to the press release statement, atai Life Sciences focuses on developing mental health treatments aimed at transforming patient outcomes.
In other recent news, atai Life Sciences announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for its BPL-003 nasal spray, aimed at treating adult patients with treatment-resistant depression. This designation is intended to accelerate the development of drugs that show significant improvement over existing therapies. Additionally, atai Life Sciences is moving forward with its acquisition plans for Beckley Psytech Limited, with the transaction expected to close in the fourth quarter of 2025, pending shareholder approval and other customary conditions. However, the company cautioned that there is no guarantee the acquisition will be completed within the anticipated timeframe.
In terms of analyst activity, H.C. Wainwright reiterated its Buy rating on atai Life Sciences, maintaining a price target of $15.00, following positive clinical data for the company’s psychedelic treatment. Similarly, Canaccord Genuity reaffirmed its Buy rating with an $11.00 price target, also citing favorable results from clinical trials involving the BPL-003 treatment. These developments underscore continued interest and confidence from analysts in atai Life Sciences’ potential for growth and innovation in the field of depression treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.